Maryam Heydari, Keyvan Ghassami,
Volume 6, Issue 2 (Summer 2003)
Abstract
Introduction: Migraine is one of the widespread discases in the word, being 15-20 percent prevalent in women, and 6 percent in men. The attacks resulting from the migraine usually range from minor to major, and even may make the patient unable to work. Its dangerous and permanenet effects may also led to paralysis of different parts of the body. Therefore, it is necessary to do more investigations concerning diagnosis and drug treatments which can prevent the migraine attacks better.
Materials and Methods: The study was a randomized controlled trial which lasted for six months. The patients have been studied through different ways including case history, checkup. electroencephalogram (EEG), computed tomography scanning, blood sampling, kidney and liver function and starting time of the treatment. Successful treatment responses to control migrainc attacks using the prophylactic drugs. Valproate Sodium and Propranolol with tricyclic antidepression drugs, i.e., Amitriptyline and/or Nortriptyline were studied.
Results: Of 126 patients studied (31.8% were men and 68.2% women), 65.1% had normal EEG and 34.9% had abnormal EEG. The patients using Valproate Sodium with normal and abnormal EEG had successful treatment responses equal to 35% and 95.6%, respectively. Additionally, other patients using Propranolol with tricyclic antidepressant Amitriptyline and/or Nortriptyline with normal and abnormal EEGs had successful treatment responses equal to 61.9% and 28.6%, respectively. Statistically, the results were significantly different. However, there were not significant differences between interactive effects of the drugs in sexes, and sexes in EEG types. The most prevalent side effects due to Valproate Sodium and Propranolol with tricyclic antidepressant drugs, i.e., Amitriptyline and/or Nortiptyline were vertigo and exhaustation, respectively.
Conclusion: This study revealed that the best treatment to prevent migraine attacks was using Valproate Sodium tablets in patients with abnormal EEGs, and using Propranolol tablets along with Amitriptyline and/or Nortriptyline for those who had normal EEG.
Farzaneh Fuladi Targhi, Fardin Faraji, Ali Akbar Maleki Rad, Keyvan Ghassami, Afsoon Talaei,
Volume 21, Issue 6 (12-2018)
Abstract
Background and Aim: Multiple Sclerosis is (MS) is a common demyelinating disease of CNS that inflammation and stress oxidative processes have an important role in clinical courses and progression of it. The aim of the present study was to determine the anti-inflammatory effects of Melatonin on fatigue in MS.
Materials and Methods: In a double-blind clinical trials study, 62 patients with relapsing remitting MS were randomized to oral Melatonin 3 mg or placebo daily for 8 weeks. Scale of Fatigue in MS was studied by assessing FSS (Fatigue Severity Scale) on weeks 1 and 8.
Findings: 47 patients in intervention group and 15 patients in placebo group completed the study. In intervention group, treatment with Melatonin produced a significant decrease in FSS vs placebo group (before intervention: the average of FSS in patient group was 32.04±13.97 and in control group was 35.86±15.44; after intervention: the average of FSS in patient group was 30.42±12.40 and in control group was 41±12.66). Although in control group, the average of FSS was 35.866 and it was 41 after intervention. Because the score of placebo patient is near or upper than 36, this study suggested that Melatonin has a significant effect on improving and decreasing fatigue in MS.
Conclusion: The use of melatonin alongside of First-line drugs such as mitoxantrone, IFN – B or glatimer acetate can improve fatigue and disability in patient with MS.
